Multimodal selenium nanoshell-capped Au@mSiO(2) nanoplatform for NIR-responsive chemo-photothermal therapy against metastatic breast cancer
- Authors
- Ramasamy, Thiruganesh; Ruttala, Hima Bindu; Sundaramoorthy, Pasupathi; Poudel, Bijay Kumar; Youn, Yu Seok; Ku, Sae Kwang; Choi, Han-Gon; Yong, Chul Soon; Kim, Jong Oh
- Issue Date
- 11-Apr-2018
- Publisher
- NATURE PUBLISHING GROUP
- Citation
- NPG ASIA MATERIALS, v.10, pp.197 - 216
- Journal Title
- NPG ASIA MATERIALS
- Volume
- 10
- Start Page
- 197
- End Page
- 216
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3868
- DOI
- 10.1038/s41427-018-0034-5
- ISSN
- 1884-4049
- Abstract
- Multimodal therapeutic agents based on novel nanomaterials for multidrug resistance have attracted increasing attention in cancer therapy. In this study, we describe the construction of a programmed mesoporous silica-capped gold nanorod covered with nano-selenium overcoat (Se@Au@mSiO(2)) nanoparticles as a multifunctional nanoplatform to incorporate materials with specific chemotherapeutic, chemoprevention, and photoablation/hyperthermia functions that collectively contribute to enhance anticancer efficacy in multidrug-resistant breast cancer. The triple-combination-based nanosized Se@Au@mSiO(2)/DOX effectively accumulates in the tumor and the release of the therapeutic cargo could be remotely manipulated by mild near-infrared (NIR) irradiation. Se@Au@mSiO(2)/DOX notably enhances the cell killing effect through induction of cell apoptosis. In addition, Se@Au@mSiO(2)/DOX inhibits tumor cell growth through cell cycle arrest and induction of apoptosis via suppression of the Src/FAK/AKT signaling pathways. Synergistic Se-photothermal-chemotherapy combination exhibits significant tumor growth suppression and delayed tumor progression in vivo. Immunohistochemistry analysis shows elevated numbers of caspase-3 and PARP-immunolabeled cells and decreased Ki-67 + and CD31 + cancer cells in the tumor mass. No noticeable signs of organ damage or toxicity are observed after treatment with Se@Au@mSiO2/DOX (NIR+), which is further supported by hematology and biochemical analyses. Thus, Se@Au@mSiO2/DOX has potential for the clinical treatment of metastatic breast cancers with little or no adverse effects.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3868)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.